Related Experiment Video
Updated: Jan 14, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Effects of Combination Treatment on Renal Endothelial Function in Type 2 Diabetes Mellitus
Merve Günes-Altan1,2, Agnes Bosch1, Kristina Striepe1
1Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Introduction:
Recently, we demonstrated that a combination therapy with empagliflozin and linagliptin (E+L) in patients with type 2 diabetes mellitus (T2DM) induce changes in renal hemodynamics. The purpose of the present study was to analyze the influence of nitric oxide (NO) activity of the renal vasculature on the described changes of the renal hemodynamic profile.
Methods:
Patients with T2DM were randomized to receive either E+L: (n = 34) or metformin and insulin glargine (M+I: n = 31), for 3 months. Renal hemodynamics were assessed using the constant-infusion input-clearance technique with p-aminohippuric acid for renal plasma flow (RPF) and inulin for glomerular filtration rate (GFR) at baseline and after treatment. Intraglomerular hemodynamics were calculated according to the model established by Gomez. The NO activity in the renal circulation was assessed by analyzing change in RPF in response to i.v. administrated NG-monomethyl-l-arginine (L-NMMA), an NO inhibitor.
Results:
After 3 months of treatment, changes in renal hemodynamic parameters were compared with baseline in both groups without any change in renal NO activity. In patients with E+L treatment, we observed a correlation between change in NO activity of the renal vasculature and change in RPF (r = -0.665, P < 0.001) after 3 months of treatment. Similar correlations with change in renal vascular resistance (RVR) (r = 0.439, P = 0.003) and resistance of the efferent postglomerular (RE) arterioles (r = 0.513, P = 0.002) were observed. No such relationships with change in renal NO activity were observed in the M+I group after 3 months of treatment.
Conclusion:
Renal NO activity emerged as a determinant of the renal hemodynamic response in the combination therapy of E+L, but not in the combination therapy of M+I. Our study provides evidence that the treatment effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors may be contributed at least partly by the renal NO activity in patients with T2DM.
Insights
Nitric oxide (NO) activity influences renal hemodynamics in type 2 diabetes mellitus (T2DM) patients treated with empagliflozin and linagliptin (E+L). This NO activity is a key factor in the renal hemodynamic response to E+L therapy.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is associated with altered renal hemodynamics.
- Previous studies showed that combination therapy with empagliflozin and linagliptin (E+L) impacts renal hemodynamics in T2DM patients.
Purpose of the Study:
- To investigate the role of nitric oxide (NO) activity in the renal vasculature on the hemodynamic changes induced by E+L combination therapy in T2DM patients.
Main Methods:
- Randomized controlled trial comparing E+L with metformin and insulin glargine (M+I) in T2DM patients for 3 months.
- Renal hemodynamics (renal plasma flow, glomerular filtration rate) assessed using clearance techniques.
- Renal NO activity evaluated by measuring changes in renal plasma flow in response to an NO inhibitor (L-NMMA).
Main Results:
- E+L treatment correlated significantly with changes in renal plasma flow (RPF), renal vascular resistance (RVR), and efferent arteriolar resistance (RE) related to NO activity.
- No significant correlations between renal NO activity and hemodynamic changes were observed in the M+I group.
- No overall change in renal NO activity was detected in either group.
Conclusions:
- Renal NO activity is a determinant of the renal hemodynamic response to E+L combination therapy in T2DM.
- The therapeutic effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, like empagliflozin, may be partly mediated by influencing renal NO activity.
More Related Videos
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Oral Hypoglycemic Agents: Biguanides and Glitazones
Heart Failure V: Medical Management

